Journal of Medical Economics, Volume 10, Issue 3 (2007)

Browse this journal
Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days

Journal of Medical Economics, Volume 10, Issue 3 (2007)

See all volumes and issues
Vol 27, 2024 Vol 26, 2023 Vol 25, 2022 Vol 24, 2021 Vol 23, 2020 Vol 22, 2019 Vol 21, 2018 Vol 20, 2017 Vol 19, 2016 Vol 18, 2015 Vol 17, 2014 Vol 16, 2013 Vol 15, 2012 Vol 14, 2011 Vol 13, 2010 Vol 12, 2009 Vol 11, 2008 Volume 10, 2007 Vol 9, 2006 Vol 8, 2005 Vol 7, 2004 Vol 6, 2003 Vol 5, 2002 Vol 4, 2001 Vol 3, 2000 Vol 2, 1999 Vol 1, 1998
Download citations Download PDFs Download issue

Research Article

Article
Cost effectiveness of oseltamivir for the treatment of influenza in adults, adolescents and children in Finland
Asko Järvinen MD PhD, Jaana Joutseno BSc (Pharm) & Marlene Gyldmark MPhil
Pages: 199-214
Published online: 11 Sep 2007
AbstractforCost effectiveness of oseltamivir for the treatment of influenza in adults, adolescents and children in Finland | Full Text | References | PDF (647.2 KB)
  • 312 Views
  • 1 CrossRef citations
  • 0Altmetric
Free Access
Article
Influence of time horizon and treatment patterns on cost-effectiveness measures: the case of allergen-specific immunotherapy with Grazax
Axelle Bériot-Mathiot MSc, Ulrik Vestenbæk MSc & Peter Bo Poulsen PhD
Pages: 215-228
Published online: 11 Sep 2007
AbstractforInfluence of time horizon and treatment patterns on cost-effectiveness measures: the case of allergen-specific immunotherapy with Grazax | Full Text | References | PDF (594.1 KB)
  • 245 Views
  • 5 CrossRef citations
  • 0Altmetric
Free Access
Article
Estimated cost savings associated with the use of valsartan in heart failure in a large US health plan
Dean G Smith PhD, Feride Frech-Tamas RPh MPH, William Randle PharmD & Ronald Preblick PharmD MPH
Pages: 229-238
Published online: 11 Sep 2007
AbstractforEstimated cost savings associated with the use of valsartan in heart failure in a large US health plan | Full Text | References | PDF (392.2 KB)
  • 181 Views
  • 0 CrossRef citations
  • 0Altmetric
Free Access
Article
Cost effectiveness of rimonabant use in patients at increased cardiometabolic risk: estimates from a Markov model
J Jaime Caro MDCM FRCPC FACP, Ipek Ozer Stillman MSc, Aurelie Danel PharmD, Denis Getsios BSc & Phillip McEwan PhD
Pages: 239-254
Published online: 11 Sep 2007
AbstractforCost effectiveness of rimonabant use in patients at increased cardiometabolic risk: estimates from a Markov model | Full Text | References | PDF (658.7 KB)
  • 521 Views
  • 19 CrossRef citations
  • 0Altmetric
Free Access
Article
A comparison of the estimated costs of erlotinib, docetaxel and pemetrexed for the second-line treatment of non-small cell lung cancer from the German healthcare perspective
Wioletta Kotowa MD, Ulrich Gatzemeier PhD MD, Olaf Pirk PhD MD, Anja Gabriel PhD MD & David Heigener PhD MD
Pages: 255-271
Published online: 11 Sep 2007
AbstractforA comparison of the estimated costs of erlotinib, docetaxel and pemetrexed for the second-line treatment of non-small cell lung cancer from the German healthcare perspective | Full Text | References | PDF (668.9 KB)
  • 384 Views
  • 9 CrossRef citations
  • 0Altmetric
Free Access
Article
Cost estimation of neonatal intensive care in Greece: the case of Athens maternity hospitals
Mary Geitona & Magdalini Hatzikou MBA
Pages: 273-283
Published online: 11 Sep 2007
AbstractforCost estimation of neonatal intensive care in Greece: the case of Athens maternity hospitals | Full Text | References | PDF (435.5 KB)
  • 434 Views
  • 2 CrossRef citations
  • 0Altmetric
Free Access
Article
Psychometric evaluation of Global Evaluation of Treatment Effectiveness: a tool to assess patients with moderate-to-severe allergic asthma
Andrew Lloyd DPhil, Florian Turk MSc, Trevor Leighton MSc & G Walter Canonica MSc
Pages: 285-296
Published online: 11 Sep 2007
AbstractforPsychometric evaluation of Global Evaluation of Treatment Effectiveness: a tool to assess patients with moderate-to-severe allergic asthma | Full Text | References | PDF (471.4 KB)
  • 2545 Views
  • 26 CrossRef citations
  • 0Altmetric
Free Access
Article
Evaluating the cost effectiveness of asthma inhaler systems: an observational study of patients in General Practice in the UK
Alan Haycox, Ruben Mujica Mota & Richard Featherstone
Pages: 297-308
Published online: 11 Sep 2007
AbstractforEvaluating the cost effectiveness of asthma inhaler systems: an observational study of patients in General Practice in the UK | Full Text | References | PDF (486.6 KB)
  • 286 Views
  • 1 CrossRef citations
  • 0Altmetric
Free Access
Article
Methodological aspects of differential item functioning in the Rasch model
John Brodersen MD GP PhD, David Meads MSc, Svend Kreiner MSc, Hanne Thorsen MD PhD, Lynda Doward MRCS & Stephen McKenna PhD
Pages: 309-324
Published online: 11 Sep 2007
AbstractforMethodological aspects of differential item functioning in the Rasch model | Full Text | References | PDF (691.1 KB)
  • 868 Views
  • 49 CrossRef citations
  • 0Altmetric
Free Access

Review

Article
Economic evaluation in health: saving money or improving care?
Dan Chisholm PhD & David B Evans PhD
Pages: 325-337
Published online: 11 Sep 2007
AbstractforEconomic evaluation in health: saving money or improving care? | Full Text | References | PDF (525.6 KB)
  • 4544 Views
  • 37 CrossRef citations
  • 0Altmetric
Free Access

Explore articles

Explore the most recently published articles

Intensive care unit improves dialysis care quality while reducing costs
Tara Greenleaf Nichols et al.
Research Letter | Published online: 7 Jun 2024
Open Access
The efficiency of TAVI in intermediate and low-risk Japanese patients
Panagiotis Petrou
Editorial | Published online: 7 Jun 2024
Open Access
Analysis of long-term clinical and cost impact of etranacogene dezaparvovec for the treatment of hemophilia B population in the United States
Songkai Yan et al.
Article | Published online: 6 Jun 2024
Open Access
Cost-effectiveness analysis of mosunetuzumab for treatment of relapsed or refractory follicular lymphoma after two or more lines of systemic therapy in the United States
Matthew Matasar et al.
Article | Published online: 6 Jun 2024
Open Access
View all latest articles